Cargando…
Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
Despite recent advances in the treatment of advanced non–small-cell lung cancer (NSCLC), bevacizumab plus platinum–based doublet chemotherapy remains a commonly used first-line regimen. This study was conducted to compare the efficacy and safety of pemetrexed–platinum with or without bevacizumab in...
Autores principales: | Li, Xin, Huang, Jie, Qiu, Yao, Zhang, Qianyun, Yang, Shaoyu, Wu, Kan, Wang, Jiaoli, Wang, Limin, Ye, Jian, Ma, Shenglin, Xia, Bing, Chen, Xueqin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138310/ https://www.ncbi.nlm.nih.gov/pubmed/34025415 http://dx.doi.org/10.3389/fphar.2021.649222 |
Ejemplares similares
-
Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Zhou, Chun-Hua, et al.
Publicado: (2021) -
Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012) -
Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases
por: Tian, Yaru, et al.
Publicado: (2019) -
Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
por: Severi, Leda, et al.
Publicado: (2018) -
MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab
por: Jing, Wang, et al.
Publicado: (2020)